Pulmonary vascular diseases
Oral presentation
Risk stratification in treatment of pulmonary arterial hypertension
Methods :
Cell and molecular biology, Epidemiology, Public health, General respiratory patient care
08:30
Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial
O. Sitbon(Le Kremlin-Bicêtre, France)
COI
1
08:45
Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study
O. Sitbon(Le Kremlin-Bicêtre, France)
COI
2
09:00
Early improvements predict outcomes in pulmonary arterial hypertension
R. White(Rochester, United States)
COI
3
09:15
ESC/ERS low-risk profile achievement accurately predicts mortality in scleroderma-associated PAH
V. Mercurio(Napoli, Italy)
COI
4
09:30
Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH)
A. Boucly(London, United Kingdom)
COI
5
09:45
Early treatment of borderline pulmonary arterial hypertension associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group, proof-of-concept study
6
10:00
emPHasis-10 score predicts mortality in patients with pulmonary hypertension
J. Wort(London, United Kingdom)
COI
7
10:15
Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model
P. Poble(Besançon, France)
COI
8
. . .
